Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2006-04-04
2006-04-04
Siew, Jeffrey (Department: 1642)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S455000, C435S328000, C424S130100, C424S133100, C424S135100, C424S136100, C424S141100, C424S142100, C530S387100, C530S387300, C530S388100, C530S388150
Reexamination Certificate
active
07022500
ABSTRACT:
Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.
REFERENCES:
patent: 4578335 (1986-03-01), Urdal et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816565 (1989-03-01), Honjo et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4845198 (1989-07-01), Urdal et al.
patent: 4867973 (1989-09-01), Goers et al.
patent: 4975467 (1990-12-01), Ku et al.
patent: 5198359 (1993-03-01), Taniguchi et al.
patent: 5225539 (1993-07-01), Winter
patent: 5476786 (1995-12-01), Huston
patent: 5530101 (1996-06-01), Queen et al.
patent: 5554515 (1996-09-01), Kurimoto et al.
patent: 5578707 (1996-11-01), Menachem et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5665774 (1997-09-01), Armistead
patent: 5674494 (1997-10-01), Strom
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5780027 (1998-07-01), Maroun
patent: 5830454 (1998-11-01), Renauld et al.
patent: 5846534 (1998-12-01), Waldmann et al.
patent: 5951973 (1999-09-01), Lee et al.
patent: 6036956 (2000-03-01), Jacob et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6329511 (2001-12-01), Vasquez et al.
patent: 6333032 (2001-12-01), Skurkovich et al.
patent: 6350860 (2002-02-01), Buyse et al.
patent: 6407213 (2002-06-01), Carter et al.
patent: 6544504 (2003-04-01), Grint et al.
patent: 6548640 (2003-04-01), Winter
patent: 2002/0025316 (2002-02-01), Ferguson
patent: 2003/0012787 (2003-01-01), Ashkenazi et al.
patent: 2003/0012790 (2003-01-01), Ashkenazi et al.
patent: 2003/0044410 (2003-03-01), Skurkovich et al.
patent: 2275692 (1998-07-01), None
patent: 2297692 (1998-08-01), None
patent: 0120694 (1984-10-01), None
patent: 0125023 (1984-11-01), None
patent: 0171496 (1986-02-01), None
patent: 0173494 (1986-03-01), None
patent: 0184187 (1986-06-01), None
patent: 0239400 (1987-09-01), None
patent: 0256654 (1988-02-01), None
patent: 0266663 (1988-05-01), None
patent: 304 291 (1988-08-01), None
patent: 0318554 (1989-06-01), None
patent: 0323806 (1989-07-01), None
patent: 0328404 (1989-08-01), None
patent: 0365997 (1990-05-01), None
patent: 0368684 (1990-05-01), None
patent: 485 471 (1990-08-01), None
patent: 387 095 (1990-09-01), None
patent: 0125023 (1991-06-01), None
patent: 0460167 (1991-12-01), None
patent: 0519596 (1992-12-01), None
patent: 0592106 (1994-04-01), None
patent: 659 766 (1995-06-01), None
patent: 695 189 (1998-11-01), None
patent: 845 007 (2001-11-01), None
patent: 2188941 (1987-10-01), None
patent: 2268744 (1994-01-01), None
patent: 2268745 (1994-01-01), None
patent: WO 86/05513 (1986-09-01), None
patent: WO 87/02671 (1987-05-01), None
patent: WO 88/07869 (1988-10-01), None
patent: WO 88/09344 (1988-12-01), None
patent: WO 89/01783 (1989-03-01), None
patent: WO 89/09622 (1989-10-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 91/09966 (1991-07-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 91/09968 (1991-07-01), None
patent: WO 92/11018 (1992-07-01), None
patent: WO 92/11383 (1992-07-01), None
patent: WO 93/02191 (1993-02-01), None
patent: WO 93/06231 (1993-04-01), None
patent: WO 94/11509 (1994-05-01), None
patent: WO 95/34324 (1995-12-01), None
patent: WO 96/05229 (1996-02-01), None
patent: WO 97/07136 (1996-08-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 97/37679 (1997-10-01), None
patent: WO 98/28001 (1998-07-01), None
patent: WO 98/41232 (1998-09-01), None
patent: WO 99/09055 (1999-02-01), None
patent: WO 00/32634 (2000-06-01), None
patent: WO 01/30300 (2000-10-01), None
patent: WO 01/51046 (2001-01-01), None
patent: WO 02/98460 (2002-06-01), None
Riechmann, L. et al, Reshaping human antibodies for therapy. Nature, 332: 323-327, 1988, Mar.
Billiau et al., “Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma,”J. Immunology, 140(5):1506-1510 (1988).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science, 247:1306-1310 (1990).
Burgess et al., “Possible Dissociation of the Heparin-binding Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,”J. Cell Biology, 111:2129-2138 (1990).
Froyen, “Potential therapeutic use of antibodies directed towards HuIFN-gamma,”Biotherapy, 10(1):49-57 (1997).
Lazar et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in different Biological Activities,”Molecular and Cellular Biology, 8(3):1247-1252 (1988).
Wendling, “Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody,”J. Rheumatology, 20(2):259-262 (1993).
Wiesenberg, “Suppression and augmentation of rat adjuvant arthritis with monoclonal anti-interferon-gamma antibody,”Clin. Exp. Immunol., 78(2):245-249 (1989).
Jacob et al., “In Vivo Treatment of (NZB× NZW)F1Lupus-Like Nephritis with Monoclonal Antibody To γ Interferon,”J. Exp. Med., 166:798-803 (1987).
Yamamoto et al., “Characterization of Mouse Monoclonal Antibodies to Human Interferon-Gamma,”Microbiol, Immunol., 32(4):339-350 (1988).
Adair et al, “Humanization of the murine anti-human CD3 monoclonal antibody OKT3,” Hum. Antibod. Hybridomas, 5, (1994), pp. 41-47.
Amit et al., “Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution.,” Science, 233 (1986), pp. 747-753.
Barton et al., Protein Sequencing Alignment and Database Screening, Protein Structure Prediction, 31-63, 1996.
Better et al. “Eschericia coliSecretion of an Active Chimeric Antibody Fragment,” Science, 240 (1988) pp. 1041-1043.
Bird et al., “Single-Chain Antigen-Binding Proteins,” Science, 242 (1988) pp. 423-426.
Boulianne et al., “Production of functional chimeric mouse/human antibody,” Nature, 312 (1984) pp. 643-646.
Caron et al., “Biological and Immunological Features of humanized MI95 (Anti-CD33) Monoclonal Antibodies,” Cancer Research, V. 52, (1992), pp. 6761-6767.
Carter et al., “Humanization of an anti-p185HER1antibody for human cancer therapy,” Proc. Natl. Acad. Sci. USA. 89 (1992) pp. 4285-4289.
Cheetham, “Reshaping the antibody combining site by CDR replacement-tailoring or tinkering to fit?”, Prot. Eng., 2(3) (1988) pp. 170-172.
Chothia et al., “The relation between the divergence of sequence and structure in proteins,” EMBO J., 5 (1986), pp. 823-826.
Chothia et al., “Transmission of conformational change in insulin,” Nature, 302 (1983) pp. 500-505.
Chothia et al., “The predicted structure of immunoglobulin DI.3 and its comparison with crystal structure,” Science, 233 (1986), pp. 755-758.
Chothia et al., “Canonical Structures for the Hypervariable Regions of immunoglobulins,” J. Mol. Biol., 196 (1987) pp. 901-917.
Chothia et al., “Conformations of immunoglobulin Hyperv
Queen Cary L.
Selick Harold E.
Holleran Anne L.
Protein Design Labs, Inc.
Siew Jeffrey
Townsend and Townsend / and Crew LLP
LandOfFree
Humanized immunoglobulins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized immunoglobulins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized immunoglobulins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3531632